Share on StockTwits

Analysts at SunTrust started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report issued on Thursday. The firm set a “buy” rating and a $57.00 price target on the stock. SunTrust’s price target indicates a potential upside of 50.55% from the company’s current price.

Shares of bluebird bio (NASDAQ:BLUE) traded down 0.45% during mid-day trading on Thursday, hitting $37.86. 193,557 shares of the company’s stock traded hands. bluebird bio has a 1-year low of $17.03 and a 1-year high of $41.75. The stock has a 50-day moving average of $35.05 and a 200-day moving average of $28.21. The company’s market cap is $1.083 billion.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.39. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.15 million. On average, analysts predict that bluebird bio will post $-1.69 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on BLUE. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of bluebird bio in a research note on Wednesday, June 18th. They now have a $53.00 price target on the stock, up previously from $44.00. Separately, analysts at Wedbush raised their price target on shares of bluebird bio to $51.00 in a research note on Monday, June 16th. Finally, analysts at Piper Jaffray initiated coverage on shares of bluebird bio in a research note on Friday, June 13th. They set an “overweight” rating on the stock.

In other bluebird bio news, CEO Nick Leschly sold 10,300 shares of bluebird bio stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $38.45, for a total transaction of $396,035.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

bluebird bio, Inc is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.